Breaking News

Lonza, Index Ventures Ink Exclusive Biologics Production Pact

By Kristin Brooks | January 9, 2014

To manufacture biologics for Index portfolio companies

Lonza and Index Ventures, a venture capital investment firm, have entered an exclusive agreement for process development and cGMP production of all biologics for Index Ventures’ portfolio of companies. The companies may add projects during the five-year agreement, as Index makes future investments.
 
“This agreement shows that Lonza’s value to a company’s product development pipeline is being recognized more widely by investors in biotech companies,” said Dr. Stephan Kutzer, chief operating officer of Lonza Pharma & Biotech. “This multi-product agreement demonstrates Lonza’s ability to offer world-class expression platforms in combination with secure manufacturing capabilities for the complete product lifecycle.” 
 
Kevin Johnson, partner at Index Ventures, said, “Lonza has manufactured the majority of the antibody products I’ve worked on in the last 20 years and proved to be an excellent partner. I’m pleased that we’re now able to extend that expertise to our asset-centric portfolio companies, enabling them to benefit as though they were much larger organizations.”

Related Packaging:

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.